Trinity Biotech PLC Q4 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : First one on the diabetes business, are all the new products that you have, the new consumables, are those all approved and ready for market or are there approvals that you need to get before you can start to sell those devices?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : So that applies to the fact that you've changed manufacturing locations for the consumable and the instruments that has all been worked out with the FDA?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : And so it sounds like by this current quarter you should be in the market with a product that has similar results but significantly lower manufacturing costs. So I would assume you'd be able to compete on price more effectively starting the second quarter of 2024. Is that correct? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 04, 2024 / 12:00PM, TRIB.OQ - Q4 2023 Trinity Biotech PLC Earnings Call

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : All right, and then if we switch over to TrinScreen, it sounds like you've made progress getting that manufacturing up and running. You've got the sales already in Kenya. Are there other markets in Africa where you can sell the product?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : So it sounds like nothing may happen in the near term, but by 2025, you do think that you'll be selling the product to other countries in Africa? Is that the --

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : Okay. All right. And then I just want to be clear, the guidance you gave for revenue and EBITDA for 2025, that includes no revenue from CGM, is that correct?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : And when do you think it's reasonable to assume that you'll start your underwriting revenue from CGM?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : All right. And then some general modeling questions. What should we use for an effective share count for 2024?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : Okay. And that includes the shares that were used to complete the divestures?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : I'm sorry, complete the acquisition, right.

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : And do you think with the cash on hand and the $6 million cash available, do you think you have enough cash to make the changes in 2024 that you want to make?

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : Okay. All right. And then you mentioned a couple of times that 2024 is off to a strong start. Can you give us any guidance on that first quarter? Or would you rather wait a couple of weeks for that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 04, 2024 / 12:00PM, TRIB.OQ - Q4 2023 Trinity Biotech PLC Earnings Call

Question: Jim Sidoti - Sidoti & Company, LLC - Analyst : All right. Seems like there's quite a bit going on. Appreciate all the color.

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : So do you have a target gross margin for 2025 that you could share or a range?

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : Okay, and in terms of the source of the growth, because it's pretty dramatic, the expected growth, do you see it evenly between point-of-care and the lab business or should it be more weighted towards one or the other? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 04, 2024 / 12:00PM, TRIB.OQ - Q4 2023 Trinity Biotech PLC Earnings Call

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : And I know in hemoglobin, you have a presence in China, you have a presence in Brazil, but going forward the next couple of years, do you see more of your growth in the US or in some of those international markets?

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : And then just two more quick ones. Did the Sjogren's test continue to grow?

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : And then the last question, the EBITDASO guidance, that includes the spending you are doing in the CGM segment?

Question: Paul Nouri - Noble Equity Fund, LP - Analyst : Okay.